EC antitrust probe homes in on Servier
This article was originally published in Scrip
Executive Summary
The European Commission has sent objections to Servier and a number of generics firms in the latest step in its investigation into anticompetitive practices by pharmaceutical companies. Servier is accused of trying to limit generic competition to its cardiovascular medicine perindopril, both by buying up scarce technologies for the product's manufacture, and by inducing generics companies to sign settlements over patent challenges.